Is Sanofi (ENXTPA:SAN) A Bargain As FDA Approval For Sarclisa Escena Expands Its Reach?

Sanofi (ENXTPA:SAN) is back in focus after US regulators cleared Sarclisa Escena, a subcutaneous version of its multiple myeloma therapy that can be delivered via on-body injector or manual injection, supported by non inferiority and safety data.

See our latest analysis for Sanofi.

Sanofi’s US approval for Sarclisa Escena comes as momentum in the stock has been mixed. The share price is at €77.1, with a 7 day share price return of 3.48%, but a year to date share price return that is down 6.34%. The 5 year total shareholder return of 10.09% contrasts with weaker 1 and 3 year total shareholder returns.

If this kind of healthcare progress interests you, it may be a good moment to look wider and use our screener to uncover 128 healthcare AI stocks

Sanofi’s mixed recent returns and fresh Sarclisa Escena approval put the focus squarely on pricing. After this move, does the current valuation still offer an appealing trade off between risk and potential reward for new buyers?

Most Popular Narrative: 20.3% Undervalued

The most followed narrative puts Sanofi’s fair value at €96.70, compared with the current €77.10 share price, and anchors that view in its long term product and pipeline ambitions.

Sanofi's ongoing focus on innovative product launches and its strong R&D pipeline highlighted by accelerating investments, multiple Phase III readouts through 2026, and continued expansion of biologics (e.g., Dupixent, amlitelimab) position the company to capture higher demand for chronic disease treatments in a world with an aging population, supporting robust long-term sales growth and EPS upside. (Revenue, EPS)

Read the complete narrative.

Want to see what sits behind that confidence in Sanofi? The narrative leans heavily on compound revenue growth, rising margins and a lower future earnings multiple that still supports a higher fair value.

Result: Fair Value of €96.70 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Sanofi’s story could look different if pricing pressure in flu vaccines intensifies, or if more late stage pipeline programs deliver mixed or disappointing results.

Find out about the key risks to this Sanofi narrative.

Next Steps

Given the mix of optimism and concern around Sanofi, it makes sense to look at the underlying data yourself and move quickly to form your own view by weighing its 4 key rewards and 2 important warning signs

Looking for more ideas beyond Sanofi?

If Sanofi has sharpened your interest in healthcare and quality stocks, do not stop here. Widen your watchlist and give yourself more options to compare.

• Target potential mispricings by scanning companies that combine quality and attractive pricing using our 212 high quality undervalued stocks
• Strengthen your income game by reviewing stocks built around reliable payouts through the 474 dividend fortresses
• Keep risk in check by zeroing in on companies with sturdier finances via the 298 resilient stocks with low risk scores

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com